AI
Eli Lilly Expands AI Capabilities with $409M Genetic Leap Partnership
Eli Lilly, AI, Genetic Leap, drug discovery, RNA specialist, pharmaceutical industry
Recursion Pharmaceuticals’ AI-Driven Drug Development Strategy Fails to Impress Investors
Recursion Pharmaceuticals, AI, drug development, investors, biotech, pharmaceuticals
Embracing Agility: Critical for the Role of QARA Professional
QARA Professional, Agility, Quality Assurance, Regulatory Affairs, Market Access, Innovative Therapeutic Solutions, AI, Technology, Regulatory Strategy, Leadership, Communication, Diversity, Inclusion.
Revolutionary AI and Brain Implants Restore ALS Patient’s Voice
ALS, brain-computer interface, AI, speech restoration, brain implants, medical breakthrough
Exscientia Merges with Recursion to Form AI-Driven Drug Discovery Leader
Exscientia, Recursion, AI drug discovery, merger, precision chemistry, small molecule synthesis, biotech consolidation
ConcertAI Partners with NVIDIA, Unveils Advanced AI Tools for Oncology Research and Treatment
ConcertAI, NVIDIA, AI tools, oncology research, clinical simulations, CARA AI platform, multi-modal oncology data, clinical trials, patient outcomes
Exscientia, AI Biotech Firm, Announces Workforce Reduction Amidst Pipeline Changes and CEO Departure
Exscientia, AI biotech, workforce reduction, pipeline cut, CEO firing, restructuring, pharmaceutical industry, drug discovery
Triomics Secures $15M for AI-Powered Clinical Trial Automation
Triomics, AI, clinical trials, automation, funding, healthcare, innovation, patient matching, drug development
Revolutionizing Cardiac Mapping: J&J’s Biosense Webster Integrates AI into Carto 3 System
J&J, Biosense Webster, AI, Carto 3 system, cardiac mapping, heart mapping, electrophysiology, medical technology, healthcare innovation.